[1] WANG JQ.Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis(2020)[J]. Journal of Diagnosis and Therapy on Dermato-Venereology(皮肤性病诊疗学杂志), 2020, 53(2): 81-88. [2] ZHAO Y, YANG HT, XUE CJ, et al.Quantitative Evaluation of Selective Janus Kinase Inhibitors for Atopic Dermatitis[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2024, 43(5): 374-379. [3] LI Y, LI M.Expert Consensus on the Treatment of Atopic Dermatitis with Systemic Janus Kinase Inhibitors[J]. Journal of Practical Dermatology(实用皮肤病学杂志), 2022, 15(3): 129-135. [4] CHEN WL, HAN DF, HE GW, et al.Advances in Clinical Biomarkers Based on the Severity of Atopic Dermatitis[J]. Chinese Journal of Modem Applied Pharmacy(中国现代应用药学), 2022, 39(13): 1762-1766. [5] ZHU X, WU WZ.Research Progress on Abrocitinib in the Treatment of Moderate and Severe Atopic Dermatitis[J]. Journal of Diagnosis and Therapy on Dermato-Venereology(皮肤性病诊疗学杂志), 2023, 30(4): 372-376. [6] ZHUANG HJ, GUO ML, LIU WW, et al.Clinical Research Progress of Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis[J]. Journal of Shanghai Jiaotong University (Medical Science)(上海交通大学学报医学版), 2021, 41(7): 963-966. [7] LIU SQ, SONG X, CHEN DY, et al.Efficacy and Safety of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis: a Systematic Review and Meta-Analysis[J]. Chongqing Medicine(重庆医学), 2023, 52(10): 1545-1550. [8] DAMSKY W, PETERSON D, RAMSEIER J, et al.The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases[J]. Journal of Allergy and Clinical Immunology, 2021, 147(3): 814-826. [9] CHEN BX, GUO J, FENG YF.A New Therapeutic Agent for Moderate to Severe Atopic Dermatitis: Abrocitinib[J]. Clinical Medication Journal(临床药物治疗杂志), 2022, 20(11): 12-16. [10] WANG SQ, ZOU GS, PAN H, et al.Mining and Analysis of Adverse Event Signals of Abrocitinib Based on FAERS Database[J].Pharmacy Today(今日药学), 2024, 34(8): 588-593. [11] ANDREW C,SHEENA D, ALLIREZA A, et al.Clinical Characteristics, Disease Course, and Outcomes of Patients with Acute Generalized Exanthematous Pustulosis in the US[J]. JAMA Dermatology, 2022, 158(2): 176-183. [12] WANG J, ZHANG SP.Advances in Acute Generalized Exanthematous Pustulosis[J]. Chinese Journal of Dermatovenereology(中国皮肤性病学杂志), 2017, 31(4): 458-461. [13] SHEN HJ, CEHNG J, YE S.A Case of Acute Generalized Rash Pust-ulosis Caused by Clindamycin[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine(浙江中西医结合杂志), 2024, 34(6): 547-548. [14] ZHANG X, QU JC, ZHAO Q, et al.Analysis of Hyponatremia Caused by Venlafaxine Hydrochloride Sustained Release Capsule: a Case Report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 819-821. [15] SCHMID S, KUECHLER PC, BRITSCHGI M, et al.Acute General-Ized Exanthematous Pustulosis[J]. The American Journal of Pathology, 2002, 161(6): 2079-2086. [16] BRITSCHGI M, STEINER UC, SCHMID S, et al.T-Cell Involvement in Drug-Induced Acute Generalized Exanthematous Pustulosis[J]. Journal of Clinical Investigation, 2001, 107(11): 1433-1441. [17] KABASHIMA R, SUGITA K, SAWADA Y, et al.Increased Circulating Th17 Frequencies and Serum IL-22 Levels in Patients with Acute Generalized Exanthematous Pustulosis[J]. Journal of the European Academy of Dermatology and Venereology, 2011, 25(4): 485-488. [18] NAVARINI AA, VALEYRIE-ALLANORE L, SETTAKA-FFETZI N, et al.Rare Variations in IL-36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis[J]. Journal of Investigative Dermatology, 2013, 133(7): 1904-1907. [19] SHIV Y, BHUTANI T, FONACIER L,et al.Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis after Switching from Dupilumab (JADE EXTEND)[J]. Journal of the American Academy of Dermatol, 2022, 87(2): 351-358. [20] FELDMEYER L, HEIDEMEYER K, YAWALKAR N.Acute Gener-alized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy[J]. International Journal of Molecular Sciences, 2016, 17(8): 1214. [21] SIDOROFF A.Acute Generalized Exanthematous Pustulosis[J]. Chemical Immunology and Allergy, 2012, 97(2): 139-148. [22] WANG LW, XU HX, CUI PG.Acute Generalized Exanthematous Pustulosis[J]. China Medical Abstract of Dermatology(中国医学文摘皮肤科学), 2016, 33(6): 700-709. [23] CHENG CE,KROSHINSKY D.Iatrogenic Skin Injury in Hospitalized Patients[J].Clinics in Dermatology, 2011, 29(6): 622-632. |